new-recommended-broker-banner new-recommended-broker-banner

Taiwan Liposome (TLC) Stock More than Doubles In Value, Here’s Why…

Updated: 7 Oct 2020

Pharmaceutical company Taiwan Liposome’s (NASDAQ: TLC) stock has jumped premarket after the company announced that the Bellberry Human Research Ethics Committee in Australia has approved the company’s Phase 1 trial of TLC19.

TLC19 is a drug that the company says has shown potential for treatment in COVID-19. 

The approval comes hot on the heels of yesterday’s acceptance of TLC’s investigational new drug application with the Taiwan Food and Drug Administration.

new-recommended-broker-banner

“We very much look forward to launching TLC19’s Phase 1 trial with the support of experienced, high-quality partners in Taiwan as well as in Australia, which has an efficient and globally recognized regulatory environment with the bonus of government incentives and benefits and is a great place to conduct clinical trials for time-sensitive projects like TLC19. 

“The receipt of this ethics approval is an important step in our clinical trial notification (CTN) application process,” said George Yeh, President of TLC.

The Phase 1 trial will evaluate the safety and tolerability of single doses in 30 healthy volunteers with the Australian government offering a rebate of 40% or more on clinical trial spending under its tax incentive program.

TLC’s share price has skyrocketed after the news, currently trading at $9, up 104.55% from yesterdays close of $4.40 per share. 

PEOPLE WHO READ THIS ALSO VIEWED:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .